Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Mutual Reliance With EU On Inspections Is Slow Going

Executive Summary

FDA still does over 40% of its inspections in Europe even as it acknowledges it must spend the money elsewhere.

You may also be interested in...



FDA Winging It With Brexit: Califf Says Agency Will React To What Happens

Commissioner says his agency does not have a plan to deal with UK's departure from the EU.

US-EU Mutual Reliance On Drug Facility Inspections Nears Reality

FDA expects to complete work this year on decision model to determine whether an EU member state's inspectorate is capable of conducting inspections that meet US requirements.

US-EU Mutual Reliance On Drug Facility Inspections Nears Reality

FDA expects to complete work this year on decision model to determine whether an EU member state's inspectorate is capable of conducting inspections that meet US requirements.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS057208

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel